Asset Details
Do you wish to reserve the book?
Annexins A2 and A5 are potential early biomarkers of hepatocarcinogenesis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Annexins A2 and A5 are potential early biomarkers of hepatocarcinogenesis
Do you wish to request the book?
Annexins A2 and A5 are potential early biomarkers of hepatocarcinogenesis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Annexins A2 and A5 are potential early biomarkers of hepatocarcinogenesis
2023
Overview
Hepatocellular carcinoma (HCC) is a highly lethal liver cancer with late diagnosis; therefore, the identification of new early biomarkers could help reduce mortality. We determine the tissue and plasma status of five annexins during hepatocarcinogenesis by diethylnitrosamine-induced cirrhosis-HCC. We found that
Anxa5
was the earliest upregulated gene at week 12 after HCC initiation, while
Anxa1
and
Anxa2
were upregulated in advanced HCC stages (weeks 18 and 22). Furthermore, the protein level of Annexin A1, A2, A5 and A10 was increased from the early stages. Immunofluorescence and subcellular fractionation revealed Annexin A1, A2, and A5 in the cytoplasm and nuclei of tumor cells. Notably, increased plasma levels of Annexin A5 significantly (r
2
= 0.8203) correlated with Annexin A5 levels in liver tissue from week 12 and gradually increased until week 22. Using the TCGA database, we found that the expression of
ANXA2
(HR = 1.7,
p
= 0.0046) and
ANXA5
(HR = 1.8,
p
= 0.00077) was associated with poor survival in HCC patients. In conclusion, we have identified Annexin A1 and A5 as potentially useful early biomarkers for poor prognosis in HCC patients.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
